| Identification | Back Directory | [Name]
Pyrido[2,3-d]pyrimidin-7(6H)-one, 4-[4-[(2S)-2-(4-chlorophenyl)-3-[(1-methylethyl)amino]-1-oxopropyl]-1-piperazinyl]-5,8-dihydro-5-methyl-, (5R)- | [CAS]
2459489-51-9 | [Synonyms]
AKT-IN-13
Pyrido[2,3-d]pyrimidin-7(6H)-one, 4-[4-[(2S)-2-(4-chlorophenyl)-3-[(1-methylethyl)amino]-1-oxopropyl]-1-piperazinyl]-5,8-dihydro-5-methyl-, (5R)- | [Molecular Formula]
C24H31ClN6O2 | [MOL File]
2459489-51-9.mol | [Molecular Weight]
470.99 |
| Hazard Information | Back Directory | [Uses]
AKT-IN-13 (compound 4b) is a potent Akt inhibitor with IC50s of 1.6 nM, 2.4 nM and 0.3 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-13 can be used for researching anticancer[1]. | [IC 50]
Akt1: 1.6 nM (IC50); Akt2: 2.4 nM (IC50); Akt3: 0.3 nM (IC50) | [References]
[1] Ma C, et al. Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors. J Med Chem. 2022 Jun 23;65(12):8144-8168. DOI:10.1021/acs.jmedchem.2c00527 |
|
|